CClinicalTrials.gg
WithdrawnNCT03704168SECAMSUpdated Nov 29, 2021

Safety and Efficacy of Cryoablation in Management of Sialorrhea in Patients With Neurological Disorders

An interventional study of CRYOABLATION in Sialorrhea and Neurologic Disorder, sponsored by Dean Nakamoto. Withdrawn. Open to participants aged 2 Years to 65 Years. Per ClinicalTrials.gov, last updated 2021-11-29.

Sponsored by Dean Nakamoto · Not applicable, Interventional, and Treatment

Why this study was withdrawn
The study was never launched.
Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
2 Years to 65 Years
Sex
All
01

Study summary

To evaluate safety of cryoablation of submandibular glands in management of sialorrhea in neurologically impaired populations.

Secondary Objective: To evaluate efficacy of cryoablation of submandibular glands in management of sialorrhea in neurologically impaired populations.

Duration:

Estimation for Recruitment: 12 months Estimation for Procedure/Trial: 1 visit with an overnight observation Estimation for Subject Follow Up: 7 days, 14 days, 28 days, 90 days, and 180 days, post ablation, with ultrasound of the bilateral submandibular glands at 28 days and 180 days post ablation Total Expected Duration for Clinical Trial: 2 years

02

Conditions studied

  • Sialorrhea
  • Neurologic Disorder
03

Who can participate

Ages eligible
2 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Written informed consent and assent (as appropriate) obtained from the subject/caregiver who opted voluntarily to participate in the procedure
  2. Male or female 2 to 65 years of age
  3. Confirmed diagnosis of sialorrhea as documented in their medical record
  4. Clinically stable with no significant changes in health status in the 2 weeks before the ablation
  5. Patients diagnosed with cerebral palsy, or other neurological impairment documented in their medical record

Exclusion criteria

Exclusion Criteria:

  1. Open sores/ulcers on skin overlying the submandibular glands
  2. Contraindications to surgery/general anesthesia e.g; coagulopathies, life threatening arrhythmias
  3. Upper respiratory airway obstruction, e.g: severe dystonia
  4. History of previous local surgery
  5. Any congenital abnormalities that may preclude cryoablation, such as vascular abnormalities or atypical size/location
  6. Patients that have received salivary gland Botulinum toxin injections within the prior 3 months
  7. Subjects unlikely to complete the study as determined by the principle investigator
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    CRYOABLATION ARM

    Device: CRYOABLATION

Interventions

  • DeviceCRYOABLATION

    The SeedNet® System induces freezing and thawing at the tip of the needle. These freezing and thawing processes are based on the Joule-Thomson effect. The unique technology of the SeedNet® System provides extremely rapid freeze and thaw operations. The system's software controls the flow of gases from the gas sources, through the manifold, to the needle and probe tips. The system can immediately switch from the freezing process to the thawing process, after which the needle can be released. This device is an FDA-cleared medical device. This IDE application is to allow for use of the commercially available device in a new clinical indication, namely cryoablation of the submandibular glands.

    Also known as: SeedNet® System

05

What researchers measure

Primary outcomes

  1. To evaluate safety of cryoablation of submandibular glands in management of sialorrhea in neurologically impaired populations.

    1. Safety Parameters: Major adverse events will be submitted to the Agency and be reviewed by the medical monitor. In case unexpected events should occur we will evaluate and report them. 2 Methods for Analyzing Safety Parameters: Prior to the enrollment of the first research subject, the study sponsor will organize and conduct an initial meeting for the medical monitor. The medical monitor will review AE logs, deviation logs, procedural details, call logs, phone scripts, study progress notes, patient medical charts, and completed questionnaires, every 5 patients, or quarterly, whichever takes place first. The sponsor-investigator will oversee the conduct of the medical monitor. Directives provided by the medical monitor will be reported accordingly and as necessary to the Food and Drug Administration and the IRB.

    Time frame: 2 years

Secondary outcomes

  1. To evaluate efficacy of cryoablation of submandibular glands in management of sialorrhea in neurologically impaired populations.

    1. Efficacy Parameters: Efficacy is defined as reduced score on the Drooling Impact Scale (range: 10-100) at baseline, 1 and 6 months interval with-in subject self-assessment. 2. Methods for Analyzing Efficacy Parameters: We will qualitatively assess the impact of drooling on patients, their families, and/or caretakers, at baseline, then twice post procedurally, using a questionnaire. The questionnaire known as the Drooling Impact Scale 'DIS' has been devised to evaluate longitudinal changes in children with neurological disorders, and quantify short- to medium-term treatment benefits of saliva-control interventions.

    Time frame: 2 years

06

Study locations

No study locations are listed for this record.

07

Registry details

Key details

Study ID
NCT03704168
Lead sponsor
Dean Nakamoto
Responsible party
Dean Nakamoto (Division Chief, Abdominal Imaging - UH Cleveland Medical Center, University Hospitals Cleveland Medical Center) — Sponsor-investigator
First posted
Oct 12, 2018
Start date
May 1, 2019 (estimated)
Primary completion
Apr 30, 2021 (estimated)
Completion
Apr 30, 2021 (estimated)
Last update
Nov 29, 2021

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion